Received: 5.16.11
First Name: F. Lennie
Last Name: Wong
Institution: City of Hope
Address 1: 1500 E. Duarte Rd.
Address 2:
City: Duarte
State/Province: California
Country: U.S.A.
Zip: 91010
Phone: 626-256-4673 x65004
Alternate Phone:
Email: lwong@coh.org

Requirements to submit AOI:

A comprehensive review of previously published data has been completed.: Yes
The specific aims are clear and focused.: Yes
The investigator has appropriate experience and expertise to develop the concept
proposal; if not, has identified a mentor or senior co-investigator.: Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks
of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

Project Title: Cost Effectiveness of COG Breast Cancer Screening Guidelines for Female Survivor of Pediatric Cancers
Planned research population (eligibility criteria): Female Childhood Cancer Survivors
exposed to 20 Gy or more of chest radiation for the treatment of childhood cancer
Proposed specific aims: Aim 1: Examine the cost-effectiveness (CE) of annual clinical
breast examination starting at puberty (age 12) until age 25, then every 6 months (CBE strategy).
Aim 2: Examine the CE of annual mammography only strategy, beginning 8 years
after diagnosis of childhood cancer but no earlier than age 25, combined with the
CBE strategy (COG recommendation, without MRI as adjunct). Aim 3: Examine the CE
of annual MRI only strategy, beginning 8 years after diagnosis of childhood cancer but
no earlier than age 25, combined with the CBE strategy (COG recommendations, without
mammography). Aim 4: Examine the CE of a contemporaneous annual mammography
and MRI strategy, beginning 8 years after diagnosis of childhood cancer but no earlier
than age 25, combined with the CBE strategy (full COG recommendation).
Will the project require non-CCSS funding to complete?: Yes
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?: We
will apply to the Leukemia and Lymphoma Society and/or to the American Cancer
Society within the next 6 months.

Does this project require contact of CCSS study subjects for . . .
Additional self-reported information: No
Biological Samples: No
Medical record data: No
If yes to any of the above, please briefly describe:

What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy: Secondary
Chronic Disease:
Psychology / Neuropsychology:
Genetics:
Cancer Control: Secondary
Epidemiology / Biostatistics: Primary

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

Late mortality: Primary
Second Malignancy: Primary

Health Behaviors

Tobacco:
Alcohol:
Physical activity:
Medical screening: Correlative Factors
Other:
If other, please specify:

Psychosocial

Insurance:
Marriage:
Education: Correlative Factors
Employment:
Other:
If other, please specify:

Medical conditions

Hearing/Vision/Speech:
Hormonal systems:
Heart and vascular:
Respiratory:
Digestive:
Surgical procedures:
Brain and nervous system:
Other:
If other, please specify:

Medications

Describe medications:

Pregnancy and offspring: Correlative Factors
Family History: Correlative Factors

Psychologic/Quality of Life

BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

Chronic conditions (CTCAE v3):
Health status:

Demographic

Age: Secondary
Race: Secondary
Sex: Secondary
Others: Secondary
If others, please specify: race/ethnicity, education

Cancer treatment

Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery: Correlative Factors

Anticipated sources of statistical support
CCSS Statistical Center:
Local institutional statistician: Yes
If local, please provide the name(s) and contact information of the statistician(s) to be involved.: F. Lennie Wong, Ph.D. (applicant)
Will this project utilize CCSS biologic samples?: No

If yes, which of the following?

Buccal cell DNA:
Peripheral blood:
Lymphoblastoid cell lines:
Second malignancy pathology samples:
Other requiring collection of samples:
If other, please explain:

Other general comments: I would also like 1) type of first cancer, 2) date of dx for 1st ca, 3) chest radiation dose for the treatment of primary cancer, 4) breast cancer (BC), including DCIS, diagnosis date, 5) estimated BC tumor dose (for those available), 6) pelvic radiation (Y/N), 7) laterality, stage, histology, estrogen receptor status of BC, 8) treatment received for BC (surgery and type of surgery, reconstruction, radiotherapy, adjuvant chemotherapy, hormonal therapy), 9) data of subsequent BC dx, 10) age at menarche, 11) age at menopause, 12) family history of BC.